Stealth BioTherapeutics Inc.
http://www.stealthbt.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Stealth BioTherapeutics Inc.
Finance Watch: Have Biopharma IPOs Hit Their Limit?
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Scenic Aims To Move 'Genetic Modifiers' Science Forward
Co-founded by Sebastian Nijman and Thijn Brummelkamp in 2017, Scenic Biotech is a spinout of the Netherlands Cancer Institute and Oxford University. It was established with a focus on identifying genetic modifiers, or genes that suppress or block the disease-causing effects of a mutated gene in the body. In Vivo spoke with incoming CEO Oscar Izeboud about the company’s next steps, and the potential for genetic modifiers to address unmet needs in the rare disease space, and beyond.
Alexion Buys A Complementary Business With Achillion
The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.
Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Stealth Peptides, Inc.